Jesús Íñigo Martínez
Biographic Data
| ID | 9997793 |
|---|---|
| NAME | Jesús Íñigo Martínez |
| GIVEN NAMES | Jesús Íñigo |
| FAMILY NAME | Martínez |
| SIGNATURE | MARTÍNEZ J I |
| AFFILIATIONS | Comunidad de Madrid |
| ORCID | 0000-0001-5375-2474 |
| VERIFIED | Yes |
| TOTAL WORKS | 1 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 1 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2024 |
| LATEST PUBLICATION YEAR | 2024 |
| H-INDEX | 0 |
The effectiveness of nirsevimab in reducing the burden of disease due to respiratory syncytial virus (RSV) infection over time in the Madrid region (Spain)
Introduction: Respiratory syncytial virus (RSV) infection is one of the main causes of morbidity and mortality from lower respiratory tract infections in children under 5 years of age worldwide. Given that, the objective of this study was estimate the effectiveness of nirsevimab (a single-dose, long-acting, human recombinant monoclonal antibody against RSV) over time for the prevention of respiratory episodes treated at different levels of care. …
No prominent works on this page.
The effectiveness of nirsevimab in reducing the burden of disease due to respiratory syncytial virus (RSV) infection over time in the Madrid region (Spain)
Introduction: Respiratory syncytial virus (RSV) infection is one of the main causes of morbidity and mortality from lower respiratory tract infections in children under 5 years of age worldwide. Given that, the objective of this study was estimate the effectiveness of nirsevimab (a single-dose, long-acting, human recombinant monoclonal antibody against RSV) over time for the prevention of respiratory episodes treated at different levels of care. …
Burden of disease (1 work) · Cohort (1 work) · Cohort study (1 work) · Disease (1 work) · Disease burden (1 work) · Environmental health (1 work) · Immunology (1 work) · Internal Medicine (1 work) · Medicine (1 work) · Pediatrics (1 work)